Email this article PRECLINICAL STUDIES OF RECOMBINANT PSEUDOMONAS VACCINE
- Authors: Mihailova N.A.1, Kaloshin A.A.1, Zimina E.M.1, Soldatenkova A.V.1, Poddubikov A.V.1
-
Affiliations:
- Mechnikov Research Institute of Vaccines and Sera
- Issue: Vol 95, No 6 (2018)
- Pages: 31-37
- Section: Articles
- URL: https://microbiol.crie.ru/jour/article/view/325
- DOI: https://doi.org/10.36233/0372-9311-2018-6-31-37
- ID: 325
Cite item
Full Text
Abstract
Aim. Evaluation of the efficacy and safety of the three experimental lots of Recombinant Pseudomonas Vaccine. Materials and methods. The preparation contained the recombinant proteins OprF and toxoid that were purified by chromatography in nickel-sepharose. Aluminum hydroxide was used as an adjuvant. The authenticity of the vaccine components was confirmed by electrophoresis and immunoblotting. The concentration of endotoxin in the vaccine was determined by LAL test. The abnormal toxicity was evaluated in mice and cavy. The anaphylactic activity was evaluated in cavy. The delayed-type hypersensitivity reaction was evaluated in mice. Evaluation of the immunogenicity was carried out in an experiment with on double immunization of mice with following intraperitoneally infection by a live virulent culture of P. aeruginosa (PA-103 strain). Results. The authenticity of the vaccine, sterility, non-pyrogenicity and non-toxicity were confirmed after the studying of the quality indicators of the three lots of Recombinant Pseudomonas Vaccine. In animal experiments, the vaccine did not possess allergic properties and it was shown that it protected mice against Pseudomonas infection with Index of efficiency 3.0 and more. Conclusion. The efficacy, the safety, and the standardization of three experimental lots of the recombinant vaccine, which is intended to prevent infections caused by P. aeruginosa, have been shown.
About the authors
N. A. Mihailova
Mechnikov Research Institute of Vaccines and Sera
Author for correspondence.
Email: noemail@neicon.ru
Russian Federation
A. A. Kaloshin
Mechnikov Research Institute of Vaccines and Sera
Email: noemail@neicon.ru
Russian Federation
E. M. Zimina
Mechnikov Research Institute of Vaccines and Sera
Email: noemail@neicon.ru
Russian Federation
A. V. Soldatenkova
Mechnikov Research Institute of Vaccines and Sera
Email: noemail@neicon.ru
Russian Federation
A. V. Poddubikov
Mechnikov Research Institute of Vaccines and Sera
Email: noemail@neicon.ru
Russian Federation
References
- Благовидов Д.А., Костинов М.П., Симонова О.И. и др. Переносимость вакцины против P. aeruginosa у детей с муковисцидозом и врожденными пороками развития легких. Эпидемиология и вакцинопрофилактика. 2016, 2 (87):55-66.
- Государственная фармакопея XIII РФ. М, 2015.
- Калошин А.А., Гатыпова Е.В., Михайлова Н.А. Получение рекомбинантных форм белка F наружной мембраны Pseudomonas aeruginosa и исследование их иммуногенных свойств. Биотехнология. 2011, 2:74-84.
- Калошин А.А., Исаков М.А., Михайлова Н.А., Вертиев Ю.В. Получение рекомбинантной атоксической формы экзотоксина А Pseudomonas aeruginosa. Бюллетень экспериментальной биологии и медицины. 2012, 154(9):330-335.
- Калошин А.А., Леонова Е.И., Солдатенкова А.В., Михайлова Н.А. Исследование протективных свойств комплекса рекомбинантного белка F наружной мембраны и рекомбинантного анатоксина Pseudomonas aeruginosa. Вестник Российской Академии Медицинских Наук. 2016, 71(1):5-10.
- Лазарева А.В., Чеботарь И.В., Крыжановская О.А. и др. Pseudomonas aeruginosa: патогенность, патогенез и патология. Клиническая микробиология и антимикробная химиотерапия 2015, 17(3):170-186.
- Миронов А.Н., Меркулов В.А., Бунатян Н.Д. и др. Руководство по проведению доклинических исследований лекарственных средств (Иммунобиологические препараты). Часть вторая. М., Издание ФГБУ «НЦЭСМП» Минздрава России, 2013.
- Остерман Л.Д. Методы исследования белков и нуклеиновых кислот, 1981.
- Doring G., Pier G.B. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine. 2008, 26(8):1011-1024.
- Le Moigne V., Gaillard J.L., Herrmann J.L. Vaccine strategies against bacterial pathogens in cystic fibrosis patients. Med. Mal. Infect. 2016 Feb;46(1):4-9.
- Ma J.G., An J.X. Deep sternal wound infection after cardiac surgery: a comparison of three different wound infection types and an analysis of antibiotic resistance. J. Thorac. Dis. 2018 Jan;10(1):377-387.
- Sambrook J.F., Russell D.W. Molecular Cloning, 2001.
- Zowalaty M.E., Thani A.A., Webster T.J. et al. Pseudomonas aeruginosa: arsenal of resistance mechanisms, decades of changing resistance profiles, and future antimicrobial therapies. Future Microbiol. 2015;10(10):1683-706.
Supplementary files
